

Figure S1 The effect of REGγ on the mantle cell lymphoma cell cycle. The percentage of shN and shR JEKO-1 cells at each phase of the cell cycle was evaluated by flow cytometry. REGγ, the proteasome activator REGγ (also known as PSME3, PA28γ, and Ki antigen); shR, REGγ-knockdown; shN, control.

https://dx.doi.org/10.21037/tcr-22-2045



Figure S2 The effect of REGγ on expression of BCL-2 and CyclinD1 proteins. (A,B) REGg had no effect on cyclin D1 and BCL2 expression. REGγ, the proteasome activator REGγ (also known as PSME3, PA28γ, and Ki antigen); BCL2, B-cell lymphoma-2.



Figure S3 The regulation of REGγ on NF-κB and IκB in different cells. The expression of P-NF-κB (ser536), IκBε and REGγ in Human Lymphoma U937 Cells, Burkkit lymphoma Namalwa cells and Mouse embryonic fibroblasts which transfected with shN and shR by Western-blot assays. REGγ, the proteasome activator REGγ (also known as PSME3, PA28γ, and Ki antigen); IκB, Inhibitor kappa B; p-NF-κB(ser536), Phospho-nuclear factor-kappa B; NF-κB, Nuclear factor-kappa B; IκBε, Inhibitor kappa B epsilon; shR, REGγ-knockdown; shN, control.

https://dx.doi.org/10.21037/tcr-22-2045